Skip to main content
. 2017 Jan 16;7(4):452–465. doi: 10.1016/j.jtcme.2016.12.006

Fig. 4.

Fig. 4

3T3-L1 cell proliferation during AP, CX. CZ, EP and OS treatment for 24 h. Significant decrease (p < 0.05) in viability was observed starting from 0.5 mg/ml for AP (Fig. 4A), CZ (Fig. 4C) and EP (Fig. 4D) and 5.0 mg/ml for CX (Fig. 4B) and OS (Fig. 4E).